Sanofi SA
PAR:SAN

Watchlist Manager
Sanofi SA Logo
Sanofi SA
PAR:SAN
Watchlist
Price: 92.77 EUR -0.62%
Market Cap: 114.4B EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one SAN stock under the Base Case scenario is hidden EUR. Compared to the current market price of 92.77 EUR, Sanofi SA is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SAN Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

2.6
P/S
P/S
Price to Sales
2.6
vs History
47
vs Industry
39
Median 3Y
2.6
Median 5Y
2.6
Industry
2.3
Forward
2.4
More Details
20.1
P/E
P/E
Price to Earnings
20.1
vs History
25
vs Industry
21
Median 3Y
17.8
Median 5Y
17.6
Industry
20.3
Forward
11.3
More Details
14.3
P/OCF
P/OCF
Price to OCF
14.3
vs History
12
vs Industry
27
Median 3Y
11.8
Median 5Y
12
Industry
15.1
More Details
18.6
P/FCFE
P/FCFE
Price to FCFE
18.6
vs History
66
vs Industry
21
Median 3Y
18.8
Median 5Y
20.5
Industry
22.3
More Details
1.5
P/B
P/B
Price to Book Value
1.5
vs History
79
vs Industry
45
Median 3Y
1.6
Median 5Y
1.6
Industry
1.9
More Details
2.8
EV/S
EV/S
Enterprise Value to Sales
2.8
vs History
57
vs Industry
37
Median 3Y
2.8
Median 5Y
2.8
Industry
2.4
Forward
2.6
More Details
3.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.9
vs History
60
vs Industry
45
Median 3Y
3.9
Median 5Y
4.1
Industry
4.8
More Details
8.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
8.8
vs History
46
vs Industry
33
Median 3Y
8.7
Median 5Y
8.8
Industry
12.2
Forward
8.3
More Details
12.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
12.9
vs History
53
vs Industry
30
Median 3Y
12.7
Median 5Y
13.1
Industry
15.2
Forward
10.1
More Details
15.1
EV/OCF
EV/OCF
Enterprise Value to OCF
15.1
vs History
15
vs Industry
26
Median 3Y
12.5
Median 5Y
12.8
Industry
13.7
More Details
29.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
29.6
vs History
15
vs Industry
15
Median 3Y
16.2
Median 5Y
16.7
Industry
17.7
More Details
1.2
EV/IC
EV/IC
Enterprise Value to IC
1.2
vs History
26
vs Industry
47
Median 3Y
1.1
Median 5Y
1.1
Industry
1.7
More Details

Multiples Across Competitors

SAN Competitors Multiples
Sanofi SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Sanofi SA
PAR:SAN
116B EUR 2.6 20.1 8.8 12.9
US
Eli Lilly and Co
NYSE:LLY
814.6B USD 18.1 76.9 44.7 49.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.9B USD 4.2 17.1 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 6.1 17.6 11.6 13.2
CH
Roche Holding AG
SIX:ROG
207.8B CHF 3.4 25.1 9.4 11
CH
Novartis AG
SIX:NOVN
187.4B CHF 4.4 18.9 11.4 14.7
UK
AstraZeneca PLC
LSE:AZN
162B GBP 4 30.7 126.2 192.8
US
Merck & Co Inc
NYSE:MRK
202.2B USD 3.2 11.8 8 9.5
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
129.1B USD 2 16.1 7.9 11.3
P/E Multiple
Earnings Growth PEG
FR
Sanofi SA
PAR:SAN
Average P/E: 26
20.1
28%
0.7
US
Eli Lilly and Co
NYSE:LLY
76.9
49%
1.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
17.6
18%
1
CH
Roche Holding AG
SIX:ROG
25.1
32%
0.8
CH
Novartis AG
SIX:NOVN
18.9
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
30.7
36%
0.9
US
Merck & Co Inc
NYSE:MRK
11.8
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.1
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
Sanofi SA
PAR:SAN
Average EV/EBITDA: 395.3
8.8
6%
1.5
US
Eli Lilly and Co
NYSE:LLY
44.7
31%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
11.6
14%
0.8
CH
Roche Holding AG
SIX:ROG
9.4
6%
1.6
CH
Novartis AG
SIX:NOVN
11.4
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
126.2
9%
14
US
Merck & Co Inc
NYSE:MRK
8
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.9
3%
2.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
Sanofi SA
PAR:SAN
Average EV/EBIT: 1 699
12.9
14%
0.9
US
Eli Lilly and Co
NYSE:LLY
49.3
33%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
16%
0.8
CH
Roche Holding AG
SIX:ROG
11
8%
1.4
CH
Novartis AG
SIX:NOVN
14.7
8%
1.8
UK
AstraZeneca PLC
LSE:AZN
192.8
21%
9.2
US
Merck & Co Inc
NYSE:MRK
9.5
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
11.3
10%
1.1

See Also

Summary
SAN intrinsic value, competitors valuation, and company profile.
DCF Valuation
SAN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SAN stock valuation using valuation multiples.
Wall Street Estimates
SAN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SAN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 248,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.